PubMed Trending Research Digest — August 18, 2026

A curated digest of 97 trending PubMed articles, automatically categorised and summarised across 15 research areas.

Jump to category

Cancer therapeutics (clinical trials, real-world outcomes, and comparative effectiveness) Cancer therapeutics (mechanisms, targets, and preclinical drug discovery) Immunotherapy and immune modulation (including checkpoints and immune niches) Epigenetics and cellular plasticity in disease (cancer and beyond) Neurodegeneration and neuroinflammation (Alzheimer’s, microglia, astrocytes, neuroimmune axes) Neurodevelopmental and neurogenetic disorders (models, gene dosage, and maturation) Neurological injury and rehabilitation (stroke, spasticity, pain, and recovery) Metabolism, microbiome, and gut–brain axis (including metabolomics and microbial therapeutics) Cardiovascular disease (risk, imaging, heart failure, and hemodynamics) Diabetes, obesity, and metabolic complications (including kidney/liver outcomes) Renal disease and urologic conditions (AKI, CKD, podocytes, RCC salvage) Respiratory disease (COPD, pulmonary hypertension, ciliary dyskinesia, pneumonia) Infectious disease (bacterial/viral infections, antivirals, and epidemiology) Hematology and coagulation disorders (ITP, CAR-T, AML/MDS, immune cell regulation) Clinical prediction, biomarkers, and trial methodology (risk stratification, prognostic tools, ML, adverse events)

Automated digest · 97 articles · 15 research areas · August 18, 2026

Overview

Across this week’s PubMed highlights, a dominant thread is the move from symptom-based or one-size-fits-all care toward mechanism-informed stratification. Multiple studies use large datasets or structured frameworks to refine risk and outcomes—ranging from computable pediatric sepsis phenotypes and AKI endotypes to metabolomic signatures for migraine and progression metrics for SCA27B. In parallel, clinical safety and effectiveness are being quantified more precisely, including adverse-event meta-analyses for diabetes/obesity drugs and real-world comparative effectiveness/cost analyses in oncology and cardiovascular disease.

A second major theme is immunology and immune regulation—both in cancer and inflammatory disease. Checkpoint efficacy is being reshaped by engineered or niche-targeted approaches (e.g., exosome/miRNA network engineering in Alzheimer’s, IL-10 trapping with PD-(L)1 blockade, and microbiome-driven immune niches in HCC). Mechanistic immunology also appears in metabolic control of immunity, such as lactate-driven STING lactylation dampening anti-tumor responses, and epigenetic-metabolic switches (e.g., Bap1 controlling eTreg differentiation and ferroptosis). Beyond cancer, targeted inflammatory pathways (IL-6 in diabetic macular edema; JAK1 inhibition in Crohn’s fibroblast programs) reflect the broader shift toward pathway-specific therapeutics.

Finally, gut–microbiome–metabolism and neurobiology continue to intersect with therapy development. Reviews and experiments connect microbial communities, metabolites, and barrier/immune signaling to disease risk and treatment response (IBS biomarker panels, SynComs as controlled live biotherapeutics, camel milk probiotic concepts, and microbiota–gut–brain links in stroke). In neurological contexts, multiple studies target neuroinflammation and cellular state control—ranging from melatonin’s gut–brain immunometabolic effects on neuropathic pain to astrocyte engineering concepts and astrocyte–synapse coupling disruptions after adolescent ethanol exposure—underscoring a growing emphasis on cellular circuitry as a therapeutic entry point.

Cancer therapeutics (clinical trials, real-world outcomes, and comparative effectiveness)

Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

This multicenter retrospective real-world study compared atezolizumab versus durvalumab, each combined with platinum-etoposide, for extensive-stage small cell lung cancer (ES-SCLC) in Japan. The key finding (as framed by the study design) is that real-world clinical outcomes and individual-level healthcare costs were assessed between patients treated with atezolizumab-containing versus durvalumab-containing regimens using Japanese health insurance claims. The significance is that it can inform treatment selection by integrating effectiveness with cost/resource utilization in routine practice.

Hirano K, Hata A, Yamanaka Y et al. · Japanese journal of clinical oncology · (2026) · View on PubMed ↗

Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.

This systematic review and meta-analysis synthesized evidence on local salvage therapies for local recurrence of renal cell carcinoma (RCC) after radical nephrectomy, partial nephrectomy, or ablation, including 47 studies (2039 patients, mostly retrospective). The key finding was an overall summary of efficacy outcomes across salvage modalities for locally recurrent disease, with recurrence patterns after primary ablation often presenting as new renal masses. Clinically, the analysis helps guide selection of salvage approaches for patients with localized recurrence, while highlighting the predominance of retrospective evidence and associated bias.

Suleja A, Alfarhan AR, Miszczyk M et al. · World journal of urology · (2026) · View on PubMed ↗

Total neoadjuvant therapy for rectal cancer: where are we now, where do we go?

This review studied the current evidence and future directions for total neoadjuvant therapy (TNT) in rectal cancer, comparing TNT regimens (induction or consolidation systemic therapy with short-course radiotherapy or chemoradiation) against standard neoadjuvant chemoradiation plus surgery with or without adjuvant chemotherapy. The key finding was that randomized trials show TNT improves pathological complete response rates and significantly improves disease-free survival, particularly in MRI-defined high-risk disease. This supports TNT as an increasingly preferred strategy for patients with high-risk rectal cancer (e.g., cT4 and cN2) to improve long-term outcomes.

Fleischmann M, Kristen A, Diefenhardt M et al. · Clinical and translational radiation oncology · (2026) · View on PubMed ↗

Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.

This study evaluated the projected lives saved and economic value of mRNA cancer immunotherapies in the United States by combining early clinical trial evidence with incidence- and demographic-based modeling. The key finding was an estimate of substantial public health and economic benefits from mRNA cancer immunotherapies, despite uncertainty and the context of reduced federal investment. Scientifically and policy-relevant, it argues that funding cuts could slow broader mRNA platform development, potentially affecting future cancer outcomes.

Wells CR, Pandey A, Bawden C et al. · Lancet regional health. Americas · (2026) · View on PubMed ↗

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

This preplanned and post-hoc analysis studied patients with newly diagnosed, advanced grade 2–3 gastroenteropancreatic neuroendocrine tumors in the randomized phase 3 NETTER-2 trial receiving [177Lu]Lu-DOTA-TATE plus long-acting octreotide. The key finding was that [177Lu]Lu-DOTATATE significantly improved progression-free survival versus control, with subgroup efficacy analyses reported by NET grade and site of origin. This supports the clinical benefit of combining peptide receptor radionuclide therapy with long-acting somatostatin analogs across relevant patient subgroups.

Ferone D, Pavel M, Herrmann K et al. · EClinicalMedicine · (2026) · View on PubMed ↗

Salvage Surgery After Proton Beam-Based Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: A Case Series Study.

This single-arm retrospective case series studied outcomes of salvage surgery after proton beam-based chemoradiotherapy (PBC) for esophageal squamous cell carcinoma (ESCC) in patients with residual or recurrent disease. The key finding was that major morbidity (Clavien-Dindo grade ≥III) and short- and long-term outcomes were characterized for this PBC-salvage setting, addressing the previously unclear safety profile compared with photon-based chemoradiotherapy. The results are clinically significant because they inform risk-benefit decisions for curative-intent esophagectomy after proton-based treatment in ESCC patients.

Kakinuma H, Honda M, Hori S et al. · Annals of surgical oncology · (2026) · View on PubMed ↗

Multi-target Therapy with Rituximab plus Mycophenolate Mofetil versus Rituximab Monotherapy in Systemic Sclerosis-Associated Interstitial Lung Disease.

This retrospective comparative study evaluated rituximab (RTX) plus mycophenolate mofetil (MMF) versus RTX monotherapy in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD), using percent-predicted forced vital capacity (FVC%) change at 2 years as the primary endpoint. The key results were framed around whether combination therapy improved ΔFVC>+5 and altered longitudinal FVC trajectories, skin involvement, and safety over up to 3 years. If combination therapy proves superior, it would inform treatment selection for SSc-ILD patients who need better lung function outcomes with acceptable tolerability.

Goswami RP, Kotha VP, Surya M · The Journal of rheumatology · (2026) · View on PubMed ↗

Lurbinectedin in the therapeutic landscape of SCLC: key clinical evidence and evolving role in the era of emerging therapies.

This narrative/critical review studied the clinical evidence and evolving role of lurbinectedin in small cell lung cancer (SCLC), particularly after relapse following platinum-based chemo-immunotherapy. It reports that lurbinectedin—an inhibitor of oncogenic transcription—shows clinically meaningful activity and has a mechanistic rationale involving transcription-dependent DNA damage, tumor microenvironment modulation, and induction of immunogenic cell death. The significance is that it frames how lurbinectedin may be positioned for combination strategies with immunotherapy and other cytotoxic agents to improve durability of control in SCLC.

Monte A, Andrini E, Stumpo S et al. · Critical reviews in oncology/hematology · (2026) · View on PubMed ↗

Research advances in the recurrence patterns of glioblastoma.

This review studied recurrence patterns in glioblastoma (GBM) by systematically analyzing studies from 1980 onward and harmonizing recurrence using anatomical distance and radiation isodose overlap classification systems. It found that local recurrence predominates, while nonlocal recurrence also occurs and is linked to determinants that remain incompletely characterized. Scientifically, mapping these patterns supports better risk stratification and could guide multimodal strategies aimed at preventing or delaying GBM recurrence.

Zhang T, Chen N, Wang J et al. · Biochimica et biophysica acta. Reviews on cancer · (2026) · View on PubMed ↗

Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

This real-world outcomes analysis used the National Cancer Database to compare perioperative chemotherapy versus preoperative chemoradiotherapy in nonmetastatic esophagogastric adenocarcinoma (n=4715). Survival analyses (Kaplan–Meier and Cox proportional hazards modeling) assessed overall survival across treatment groups including preoperative chemotherapy, perioperative chemotherapy, and preoperative chemotherapy followed by chemoradiation, as well as preoperative chemoradiotherapy. The significance is that it informs comparative effectiveness of common multimodal strategies in routine clinical practice for esophagogastric adenocarcinoma.

Oyenuga M, Goyal S, Hannan LM et al. · Cancer · (2026) · View on PubMed ↗

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated survival outcomes of second-generation androgen receptor signaling inhibitors (ARSIs) plus androgen deprivation therapy (ADT) versus conventional hormonal therapy (ADT alone or combined androgen blockade) in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC). The key finding was that ARSI-based therapy confers an overall survival benefit even in the Japanese treatment context where combined androgen blockade is commonly used rather than ADT alone. This supports the clinical effectiveness of ARSI regimens for Japanese mCSPC practice and helps interpret how comparator choice affects observed survival gains.

Iwamoto H, Izumi K, Hori T et al. · International journal of urology : official journal of the Japanese Urological Association · (2026) · View on PubMed ↗

Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis.

This systematic review and meta-analysis assessed remission outcomes of different treatments in TP53-mutated diffuse large B-cell lymphoma (TP53m DLBCL), including 1,164 patients across 31 studies. In newly diagnosed disease, targeted therapy plus chemotherapy showed pooled complete remission (CR) of 60% and pooled overall response rate (ORR) of 80%, while outcomes in the relapsed/refractory setting were also synthesized. These findings clarify which therapeutic approaches yield better response rates in TP53m DLBCL, supporting treatment selection and trial design in a high-risk molecular subgroup.

Zhou X, Jiang Y, Li A et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Cancer therapeutics (mechanisms, targets, and preclinical drug discovery)

Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies.

The study developed and tested a novel dual protein degrader, GT19630, that binds MYC and GSPT1 in MYC-driven hematologic malignancies. GT19630 disrupted a MYC–GSPT1 feedforward loop, induced integrated stress response and TCA-cycle inhibition leading to oxidative phosphorylation abrogation, and triggered apoptosis at low nanomolar concentrations with superior activity versus GSPT1-targeting molecular glues. This provides a new therapeutic strategy for previously intractable MYC biology by degrading both MYC and its translation-termination partner GSPT1.

Nishida Y, Impedovo V, Ayoub E et al. · Blood · (2026) · View on PubMed ↗

Targeting PKM2 and GAPDH by baicalein and corilagin from TCM reduces lactylation and enhance cisplatin sensitivity in lung cancer.

This preclinical study tested whether the Traditional Chinese Medicine compounds baicalein and corilagin target PKM2 and GAPDH to reduce lactylation and enhance cisplatin sensitivity in lung cancer. Using a lactate-producing key enzyme protein stability chip (L-PTSC) to identify targets and interventions, the key finding is that baicalein/corilagin reduce lactylation and thereby increase cisplatin sensitivity. This is significant because it supports a metabolism-lactylation–chemotherapy combination strategy for improving lung cancer treatment efficacy.

Li C, Cui Z, Sun W et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Enhancing Adeno-Associated Virus 2 Capsid Engineering Through Co-Evolutionary Coupling.

This study developed an AAV2 capsid engineering approach that combines co-evolutionary coupling with consensus-based design to improve manufacturing yield, stability, and efficacy. By designing 110 capsid mutants at selected sites and applying co-evolutionary coupling to guide semi-rational mutations, the key finding is that this strategy can better navigate multi-property constraints than purely rational design or undirected directed evolution. The significance is that improved AAV2 capsids could enhance gene therapy translation by increasing vector performance and reliability.

Laosinwattana S, Li Y, Sanchez BC et al. · Biotechnology and bioengineering · (2026) · View on PubMed ↗ · Free PDF ↗

Metabolic reprogramming in pancreatic cancer: interplay of glucose, lipid, and amino acid metabolism in tumor progression.

This article systematically reviewed how metabolic reprogramming—specifically glucose, lipid, and amino acid metabolism—drives pancreatic cancer progression and treatment resistance. The key finding was that dysregulated nutrient metabolism is a core, persistent hallmark across pancreatic cancer initiation, progression, and chemotherapy/targeted/immunotherapy resistance. Clinically, mapping these metabolic dependencies could identify actionable biomarkers and therapeutic targets to improve outcomes in pancreatic cancer.

Zhang Z, Tian Y, Zhang B et al. · Cytotechnology · (2026) · View on PubMed ↗

Imbalanced p53-RB signaling triggers cGAS-STING-mediated immune activation in early oral cancer development.

This study investigated how combined p53-RB pathway alterations drive early oral cancer development by triggering cGAS-STING-mediated immune activation, using Cdkn2a knock-in (R80X) mice with Trp53 loss-of-function mutants exposed to the carcinogen 4-nitroquinoline-1-oxide (4NQO). The key finding was that partial Cdkn2a loss with Trp53 heterozygosity increased STING-related inflammatory signaling and enhanced T-cell/NK-cell immune infiltration, coinciding with delayed malignant progression. Scientifically, it links imbalanced p53-RB signaling to innate immune activation via cGAS-STING as a determinant of early oral carcinogenesis dynamics.

Lu Z, Mouri Y, Shao W et al. · Oncogene · (2026) · View on PubMed ↗

Automated synthetic cell-based screening for designed proteins with emergent functions.

This paper introduced PUREdrop, an automated microfluidic platform for encapsulating and expressing protein libraries in thousands of picoliter-sized synthetic cells per construct to enable screening for designed proteins with emergent functions. The key finding was that PUREdrop provides the spatiotemporal resolution and cell-like confinement needed for bottom-up synthetic biology screening beyond conventional bulk assays. Scientifically, it advances scalable Design-Build-Test-Learn workflows for discovering protein functions that require emergent, spatially organized behavior.

Al Nahas K, Frohn BP, Šakanović A et al. · Nature communications · (2026) · View on PubMed ↗

Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation.

This medicinal chemistry study investigated a PROTAC-based approach to degrade KRAS G12D by designing and synthesizing 20 KRAS G12D PROTACs based on an MRTX1133 derivative. The lead compound (VI-1) achieved substantial KRAS G12D degradation in PANC-0203 cells, reaching 69% effective degradation at 10 μM after linker optimization and multi-cell line screening. The significance is that it advances a potentially druggable strategy for the previously “undruggable” KRAS G12D target using targeted protein degradation.

Jiang L, Yang W, Liu Y et al. · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · (2026) · View on PubMed ↗

EBV-Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma.

This study investigated how Epstein-Barr virus (EBV) drives metabolic reprogramming to promote polyamine anabolism and cisplatin resistance in nasopharyngeal carcinoma (NPC) cells. EBV upregulated the rate-limiting polyamine biosynthesis enzyme ODC1 via transcriptional activation by EBV-BZLF1 through direct promoter binding, and the resulting ODC1–spermidine axis enhanced viral replication and conferred cisplatin resistance. Mechanistically linking EBV-BZLF1 to ODC1-mediated polyamine metabolism provides a potential targetable pathway to overcome chemotherapy resistance in EBV-associated NPC.

Li Y, Hu X, Yang C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Electronic Chip-Mimetic Medical Implants for Controllable Sonothermal Treatments.

This study developed and tested an implantable “electronic chip-mimetic” sonothermal platform using metal–semiconductor heterogeneous interfaces on pretreated titanium (pTi). Using magnetron sputtering to coat pTi with TiO2, Si, ZnO, or Te, the authors found ultrasound irradiation produced distinct in situ temperature rises (ΔT > 18°C in 15 minutes) for semiconductor coatings, whereas conductor coatings did not. The results support a materials/engineering route to controllable, sterilizable sonothermal medical implants for localized therapy.

Zhang Z, Liu P, Lei J et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Immunotherapy and immune modulation (including checkpoints and immune niches)

Intratumoral Bacillus cereus orchestrates stem-like lymphoid niches to potentiate immunotherapy response in hepatocellular carcinoma.

The study used spatial multi-omics to define immune niches in hepatocellular carcinoma (HCC) and tested how intratumoral Bacillus cereus affects responses to PD-1/PD-L1 blockade. It identified stem-like lymphoid niches (SLNs) characterized by CD70+ type 2 innate lymphoid cells (ILC2s) and progenitor exhausted T (Tpex) cells, and showed that B. cereus promotes SLN accumulation via endothelial IL-33 release, enhancing immunotherapy efficacy. This mechanistic niche-level biomarker and microbiome-driven pathway could improve prediction and potentiation of checkpoint therapy in HCC.

Hu C, You W, Huang Y et al. · Cancer cell · (2026) · View on PubMed ↗

Serum IgA proteomics reveals clonal composition and neutralization of dimeric and monomeric IgA repertoires against human norovirus.

The study applied serum LC-MS/MS proteomics to characterize clonal IgA repertoires (monomeric IgA and dimeric IgA) and their neutralizing epitopes against human norovirus in human subjects. It found that antigen-specific IgA clonotypes are largely shared between mIgA and dIgA (with >80% of antigen-specific mIgA also detectable as dIgA) and established clonal relationships between circulating IgG and IgA as well as between dIgA and mIgA. These findings clarify how IgA dimerization contributes to norovirus neutralization and can inform vaccine/antibody design targeting GII.4.

Park J, Jo G, Reyes Y et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

This multicenter retrospective cohort study evaluated real-world outcomes of topical ruxolitinib 1.5% cream in non-segmental vitiligo across 34 Italian dermatology centers, including patient-reported mental health and quality-of-life measures in 860 patients aged ≥12 years. It assessed repigmentation (via F-VASI7) and safety while identifying clinical predictors of treatment response. These findings extend phase-3 evidence by showing how topical JAK inhibition performs in heterogeneous real-world populations and which baseline factors may forecast benefit.

Marzano AV, Narcisi A, Tavoletti G et al. · The British journal of dermatology · (2026) · View on PubMed ↗

Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.

This review summarized emerging therapeutic opportunities targeting nonclassical MHC-I molecules, including HLA-E, HLA-F, HLA-G, MR1, and CD1 family members, across cancer, infection, autoimmunity, and transplantation. It reports that advances in structural immunology, single-cell and spatial profiling, and engineered immune cell technologies are clarifying distinct immunobiology and enabling new therapeutic concepts. The significance lies in accelerating translation of nonclassical MHC-I biology into targeted immunotherapies with potentially improved specificity and immune regulation.

Li YR, Chen Y, Yang L · Trends in molecular medicine · (2026) · View on PubMed ↗

Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses.

The study evaluated a bispecific anti-PD-L1/IL-10-trap antibody designed to simultaneously block PD-(L)1 and trap IL-10, testing how IL-10 concentration affects T-cell function in cancer settings. The authors found that very high exogenous IL-10 induced IFNγ production by T cells, whereas IL-10 levels comparable to those in patients suppressed T-cell activity, and that dual targeting enhanced T-cell responses. This supports a therapeutic strategy of combining PD-L1 checkpoint blockade with IL-10 pathway neutralization to overcome IL-10–mediated immune suppression in cancer patients.

Singh L, Zabavnik N, Venkatasubramanian S et al. · Molecular therapy. Oncology · (2026) · View on PubMed ↗

Upadacitinib effectively suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn’s disease tissue.

This experimental study examined whether upadacitinib suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn’s disease tissue, using 19 independent phIF cultures. In CD-derived phIFs, IL13RA2 regulation was tested in the context of anti-TNF-α infliximab and the JAK1 inhibitor upadacitinib, with the key finding that upadacitinib effectively reduced IL13RA2 expression. Clinically, this supports a mechanistic rationale for JAK1 inhibition in Crohn’s disease fibroblast programs associated with inflammation and anti-TNF resistance.

Wang L, Wu R, de Jong S et al. · Biochemical pharmacology · (2026) · View on PubMed ↗

Pulsatilla saponin D triggers SHP2-mediated mitochondrial dysfunction and ferroptosis to augment cancer immunotherapy.

Pulsatilla saponin D (PSD), a natural triterpenoid, was studied as an immunogenic cell death (ICD) inducer to potentiate immune checkpoint therapy in cancer models, with mechanistic focus on SHP2-mediated mitochondrial dysfunction and ferroptosis. The key finding was that PSD triggers SHP2-dependent mitochondrial impairment and ferroptosis, thereby increasing ICD and improving the efficacy of immune checkpoint therapy. This provides a natural-product-based mechanism to convert immunosuppressive tumor microenvironments into more immunogenic states for better ICT responses.

Sun C, Li L, Dong J et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Lactate-Induced K370 Lactylation of STING Inhibits STING-TBK1 Signaling and Dampens Anti-Tumor Immunity.

This work examined how lactate alters innate immune signaling by inducing lactylation of STING at lysine 370 (K370) in anti-tumor contexts. Lactate-driven K370 lactylation weakened STING–TBK1 interactions and shifted STING ubiquitination toward K48-linked degradation while reducing K63-linked ubiquitination, thereby limiting STING oligomerization/stability and dampening anti-tumor immunity. The identification of STING K370 lactylation as a metabolic checkpoint suggests a strategy to sensitize tumors to STING-targeted immunotherapies.

Wu Y, Wang J, Chen X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Synovial lining macrophages form during early postnatal life via fetal-derived CX3CR1+ cells and AQP1+ intermediates.

This study investigated how synovial lining macrophages develop during early postnatal life in mice, focusing on cellular origins and intermediate states. Using genetic mouse models, imaging, and single-cell transcriptomics, the authors found that the macrophage lining layer forms over the first weeks of life in a CSF1-dependent process largely independent of monocytes, originating from fetal-derived CX3CR1+ cells and passing through AQP1+ intermediates. Understanding this developmental pathway clarifies how the synovial barrier is established and may inform regenerative or anti-inflammatory strategies for joint diseases.

Magalhaes MS, Malengier-Devlies B, Seuzaret G et al. · Cell reports · (2026) · View on PubMed ↗

Interleukin-6 as a therapeutic target in Diabetic macular edema: current evidence and future perspectives.

This review focused on interleukin-6 (IL-6) as a therapeutic target in diabetic macular edema (DME), particularly for patients with incomplete responses to anti-VEGF therapy. It summarized evidence that IL-6 drives inflammation, blood-retinal barrier disruption, and retinal vascular dysfunction, including the relevance of elevated intraocular IL-6 levels. The clinical significance is that IL-6 pathway targeting could provide VEGF-independent treatment options for DME.

Noma H, Mimura T · Expert opinion on therapeutic targets · (2026) · View on PubMed ↗

Epigenetics and cellular plasticity in disease (cancer and beyond)

FANCJ and RTEL1 facilitate pre-replication complex disassembly following replisome collision.

Using single-molecule imaging in Xenopus laevis egg extracts, the study examined how FANCJ and RTEL1 promote disassembly of inactive MCM2-7 pre-replication complexes (pre-RCs) when replisomes collide with dormant origins. The key finding was that efficient pre-RC removal upon replisome collision requires FANCJ and RTEL1 activity, enabling replication to proceed past dormant origins. This mechanistic insight links genome stability factors to replication fork progression and helps explain how defects in these pathways can contribute to replication stress and genome instability.

Cameron G, Negi S, Sato K et al. · Cell reports · (2026) · View on PubMed ↗

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

This work studied synergistic cell-cycle repression from co-targeting HDAC and EZH2 in diffuse midline glioma driven by the H3K27M oncohistone, using patient-derived DMG glioma stem cell (GSC) cultures and orthotopic in vivo models. The key finding was that HDAC/EZH2 co-targeting produced stronger anti-tumor effects than single-agent epigenetic therapy, accompanied by global histone-modification changes and altered cell-cycle distributions in H3K27-altered DMG models. Clinically, it provides mechanistic rationale for HDAC/EZH2 inhibitor-based regimens in H3K27M-driven DMG where single epigenetic approaches have been limited.

Zhen Z, Gao Q, Ai Y et al. · Molecular therapy. Oncology · (2026) · View on PubMed ↗

Bap1-mediated deubiquitination determines immune tolerance and anti-tumor immunity via modulating eTreg cell differentiation and ferroptosis.

This mechanistic study examined how the histone deubiquitinase Bap1 regulates immune tolerance and anti-tumor immunity by controlling effector regulatory T (eTreg) cell differentiation and ferroptosis. The key finding was that Treg-specific deletion of Bap1 impaired rTreg-to-eTreg differentiation through H2A deubiquitination and metabolic reprogramming, promoted ferroptosis, and ultimately caused a fatal systemic autoimmune syndrome. These findings are significant because they identify Bap1 as an epigenetic-metabolic switch that could be targeted to modulate eTreg function and improve anti-tumor immune responses.

Liu H, Su Y, Chen D et al. · Cell death and differentiation · (2026) · View on PubMed ↗

Epigenetic reprogramming of lineage switching in cancer.

This review discussed how epigenetic reprogramming enables lineage switching and plasticity in cancer, covering changes in chromatin accessibility, histone modifications, DNA methylation, and noncoding RNA activity. It emphasized that these nonmutational epigenetic mechanisms allow tumor cells to adopt therapy-resistant, metastatic phenotypes across a spectrum beyond epithelial–mesenchymal plasticity, including neuroendocrine and stem-like states. The significance is that epigenetic regulators may represent actionable targets to prevent or reverse cancer cell plasticity and improve treatment durability.

Boyvatlı E, Akman B, Bağırsakçı E et al. · FEBS letters · (2026) · View on PubMed ↗ · Free PDF ↗

Neurodegeneration and neuroinflammation (Alzheimer’s, microglia, astrocytes, neuroimmune axes)

Written in the Stars: Astrocyte Biology From Evolution to Disease.

This article reviewed astrocyte biology from evolutionary origins through roles in brain homeostasis and disease, focusing on how astrocyte diversification contributes to nervous system pathology. It highlights that astrocytes regulate synaptic connectivity and information processing, and that modern tools (e.g., structural immunology, single-cell and spatial profiling, and engineered immune cell technologies) have expanded understanding of astrocyte functions in disease. The synthesis is significant because it frames astrocytes as actionable targets for future mechanistic and therapeutic research across neurological disorders.

Falcone C, Arckens L, Baiula M et al. · Acta physiologica (Oxford, England) · (2026) · View on PubMed ↗

Kaempferol attenuates microglial activation in Alzheimer’s disease via inhibiting the cytosolic HK2-mediated NF-κB signaling pathway.

Kaempferol was studied in 3×Tg-AD mice and LPS-stimulated BV2 microglial cells to determine how it reduces microglial activation and neuroinflammation via inhibition of cytosolic HK2-mediated NF-κB signaling. Using HK-TAT peptide to induce HK2 mitochondrial dissociation and 3-BP as an HK2 inhibitor, the study found that kaempferol suppresses the HK2/NF-κB inflammatory pathway and attenuates microglial activation. These findings support kaempferol as a mechanistically targeted anti-inflammatory candidate for Alzheimer’s disease.

Wang M, Guo M, Li S et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Restoration of Neuronal Metabolism and Memory in Alzheimer’s Disease by Reprogramming the Exosomal microRNA Network.

This study investigated whether reprogramming the exosomal microRNA (miRNA) network can restore neuronal metabolism and memory in Alzheimer’s disease (AD). The key finding was that altering the exosomal miRNA cargo improved metabolic dysfunction and memory-related outcomes, consistent with AD being driven by deeper metabolic defects rather than only amyloid-β and tau pathology. Clinically, this suggests exosome/miRNA network engineering as a candidate precision therapeutic approach for AD targeting mitochondrial and insulin/glucose-energy homeostasis.

Anwer T, Verma A, Asiri A et al. · Journal of molecular neuroscience : MN · (2026) · View on PubMed ↗

Neurodevelopmental and neurogenetic disorders (models, gene dosage, and maturation)

Adolescent alcohol exposure disrupts astrocyte-synaptic structural and functional coupling in the male dorsal hippocampus.

This study examined whether adolescent intermittent ethanol (AIE) exposure disrupts astrocyte–synaptic structural and functional coupling in the male dorsal hippocampus in a rodent model. The key finding was that AIE produced persistent astrocyte dysfunction that translated into impaired astrocyte-synaptic crosstalk, aligning with long-lasting behavioral vulnerability observed into adulthood. Mechanistically, it supports astrocyte–synapse coupling as a target pathway underlying enduring neurobiological consequences of adolescent binge-like alcohol exposure.

Coulter O, Walker CD, Carter T et al. · Molecular psychiatry · (2026) · View on PubMed ↗

Neurabin I haploinsufficiency disrupts ion channel regulation and synaptic maturation in human cortical neurons in neurodevelopmental disorders.

This study investigated how Neurabin I haploinsufficiency (PPP1R9A+/−) affects human cortical neuron maturation using isogenic CRISPR/Cas9-engineered iPSCs differentiated into cortical neurons. PPP1R9A+/− neurons showed hyperspinogenesis and increased neuritic complexity, consistent with aberrant synaptic/structural maturation. These findings provide mechanistic evidence that PPP1R9A dosage loss can directly drive neurodevelopmental disorder phenotypes and support PPP1R9A as a target for future intervention strategies.

Zehra B, Mohamed N, Tambi R et al. · Molecular psychiatry · (2026) · View on PubMed ↗

Neurological injury and rehabilitation (stroke, spasticity, pain, and recovery)

Reprogramming lineage-traced Müller glia for robust proliferation and neurogenesis in adult mammalian retinas.

In adult mammalian retinas, the study used AAV-mediated gene transfer of Ascl1 combined with activation of FGF2/MAPK signaling to reprogram lineage-traced Müller glia for cell-cycle re-entry and neurogenesis in mice. The key finding was that FGF2/MAPK activation after Ascl1 transfer robustly stimulated proliferation of lineage-traced Müller glia independent of neurotoxic injury, and that adding retinoic acid further enhanced neurogenesis. This provides a lineage-tracing-supported route to safer, more controllable glia-to-neuron conversion for retinal regenerative therapy.

Xie Y, Xin Y, Zapadka TE et al. · Cell reports · (2026) · View on PubMed ↗

Postoperative Analgesia and Recovery with Liposomal Bupivacaine TAP/RSB Block in Elderly Patients Undergoing Laparoscopic Inguinal Hernia Repair: A Randomized Controlled Trial.

This randomized controlled trial studied whether liposomal bupivacaine (LB) delivered via dual-plane TAP (transversus abdominis plane) plus rectus sheath block (RSB) improves postoperative analgesia and recovery in 147 elderly patients (≥70 years) undergoing laparoscopic TAPP inguinal hernia repair, compared with standard bupivacaine (BP) TAP+RSB or no block. The key finding was that LB-TAP+RSB reduced 48-hour opioid consumption and improved recovery outcomes versus BP-TAP+RSB and control (with standardized anesthesia targeting BIS 40–60). These results support LB-based TAP+RSB as an opioid-sparing regional analgesia strategy to enhance early mobilization and recovery in older adults after laparoscopic hernia surgery.

Gu J, Szmuk P, Yang X et al. · Drug design, development and therapy · (2026) · View on PubMed ↗

Digital screen exposure and migraine burden: a systematic review and meta-analysis.

This systematic review and meta-analysis assessed the association between digital screen exposure and migraine/headache burden across pediatric, adolescent, and adult populations. The key finding was that screen exposure is associated with migraine/headache outcomes including frequency, severity, disability, and related secondary measures, and the paper also summarizes proposed neurobiological mechanisms. Clinically, it supports considering screen exposure as a modifiable trigger in migraine management and motivates mechanistic and interventional studies.

Gowda N, Harish S, Tej G · Journal of neurology · (2026) · View on PubMed ↗

Astrocyte engineering.

This Review studied the concept of “astrocyte engineering,” focusing on how astrocyte molecular access, sensing, and effector modules can be intentionally designed to interrogate or modify brain states. It highlights engineering logic enabled by genetic access and signaling perturbation to control astrocyte interface biology across spatial and temporal scales. The scientific significance is that it provides a framework for translating astrocyte biology into targeted tools for research and potentially brain repair.

Motoyoshi M, Nagai J · Neuroscience research · (2026) · View on PubMed ↗

Efficacy of dry needling in reducing spasticity after stroke: A systematic review and meta-analysis.

This systematic review and meta-analysis studied the efficacy of dry needling (DN) for reducing post-stroke spasticity in adults by pooling randomized controlled trials that measured Modified Ashworth Scale (MAS) and Modified Modified Ashworth Scale (MMAS). Across 11 RCTs (276 patients), DN was evaluated for its effect on spasticity outcomes compared with control conditions, including DN as monotherapy or as part of multimodal interventions. Clinically, the findings aim to clarify whether DN should be incorporated into rehabilitation protocols for stroke-related spasticity.

Yuan X, Wang Z, Zhang H et al. · Complementary therapies in medicine · (2026) · View on PubMed ↗

Extracellular CIRP Dysregulates Microglial Efferocytosis in Acute Ischemic Stroke via the TLR4/miR-155/MafB Axis.

This study investigated the role of extracellular cold-inducible RNA-binding protein (eCIRP) in microglial efferocytosis during acute ischemic stroke using a transient middle cerebral artery occlusion (tMCAO) mouse model. eCIRP release into cerebrospinal fluid reduced microglial MerTK efferocytic receptor expression after tMCAO, and CIRP deficiency improved efferocytosis and resolution-associated outcomes via a TLR4/miR-155/MafB regulatory axis. Defining this eCIRP–TLR4/miR-155/MafB–MerTK pathway highlights a mechanistic target to reduce neuroinflammation and improve recovery after ischemic stroke.

Lapin D, Aylar D, Sharma A et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Melatonin Ameliorates Neuropathic Pain in Mice by Regulating Pyroptosis Through Gut Microbiota-Mediated Linoleic Acid.

This preclinical study tested whether oral melatonin (100 mg/kg for 14 days) ameliorates neuropathic pain in mice subjected to chronic constriction injury (CCI), focusing on gut microbiota–mediated linoleic acid and pyroptosis pathways. Melatonin reduced mechanical allodynia and thermal hyperalgesia and regulated pyroptosis in a manner linked to changes in gut microbiota and linoleic acid availability. These findings support melatonin as a potential gut–brain immunometabolic therapeutic strategy for neuropathic pain by targeting pyroptosis-related inflammation.

Wang Y, Yuan B, Li Y et al. · Molecular neurobiology · (2026) · View on PubMed ↗

Metabolism, microbiome, and gut–brain axis (including metabolomics and microbial therapeutics)

Mediterranean diet and health outcomes in idiopathic inflammatory myopathies.

This study evaluated Mediterranean diet (MedDiet) adherence across idiopathic inflammatory myopathies (IIM) subtypes and examined associations with patient-reported health outcomes in adults enrolled in the international COVAD-3 survey. MedDiet adherence was measured using the 14-item Mediterranean Diet Adherence Screener (MEDAS), and linear regression models were used to identify demographic, disease-related, and socioeconomic determinants of adherence and its relationship to health outcomes. If MedDiet adherence is linked to better patient-reported outcomes across IIM phenotypes, it would support diet as a modifiable adjunct strategy in IIM management.

Saha S, Minikumari Rahulan L, Sarkar M et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗

Camel milk-based probiotics: functional properties, gut health benefits, and emerging implications for the gut-brain axis-a comprehensive review.

This comprehensive review evaluated camel milk-based probiotics, focusing on their functional properties and gut health effects, including potential mechanisms linking gut microbiota metabolites to the gut-brain axis. The key finding was that camel milk’s bioactive protein components (e.g., lactoferrin and lysozyme) and antimicrobial/immunomodulatory features may make it a promising delivery matrix for probiotics, with downstream effects on gut homeostasis and gut-brain signaling via metabolites such as SCFAs and neuroactive compounds. Scientifically, it consolidates emerging evidence and mechanistic hypotheses that could guide future clinical trials of camel milk probiotic formulations for gastrointestinal and neurobehavioral outcomes.

Vazirzadeh M, Vatankha ML, Morales MA et al. · Journal of food science and technology · (2026) · View on PubMed ↗

Topical Recombinant Human Type III Collagen for Atopic Dermatitis: Evaluation of Efficacy and Safety.

This preclinical study evaluated topical recombinant human type III collagen (rhCol III) for atopic dermatitis using an ovalbumin (OVA)-induced murine model. Topical rhCol III ameliorated skin lesions, reduced scratching and epidermal thickening, and suppressed mast cell infiltration and Th2-associated cytokines (IL-4, IL-13, and TSLP). These results support rhCol III as a biomimetic, non-animal-derived topical candidate that may modulate inflammatory pathways relevant to chronic atopic dermatitis.

Liang J, Chen S, Tao L et al. · European journal of pharmacology · (2026) · View on PubMed ↗

Multi-Omics Integration Identifies a CDH3-Associated Malignant Epithelial State and Immunosuppressive Niche to Predict Prognosis in Thymic Epithelial Tumors.

This study used multi-omics approaches—including single-cell RNA sequencing, spatial transcriptomics, multiplex immunofluorescence, bulk transcriptomics, functional assays, xenografts, and computational pathology—to define malignant epithelial states and immunosuppressive niches in thymic epithelial tumors (TETs). It identified a CDH3-associated malignant epithelial state enriched for stem-like and EMT-related features and linked it to spatially organized immunosuppression, enabling prognosis prediction. Clinically, the CDH3-associated state and niche provide biomarkers and potential therapeutic stratification targets for aggressive TET subtypes.

Feng Y, Chen J, Xia L et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Dietary soy fiber limits Salmonella infection by disrupting the self-reinforcing loop between pathogen virulence and host inflammation.

This study tested whether dietary soy fiber (SF) limits Salmonella Enteritidis infection and identified the responsible microbial metabolite and host/pathogen mechanisms. Dietary SF increased colonization resistance by suppressing S. Enteritidis virulence and inflammatory amplification, with harmaline (HAL) derived from Akkermansia disrupting tetrathionate respiration, inducing oxidative stress, and inactivating Fur to suppress HilD-dependent virulence while enhancing type I interferon signaling and SUMOylation of AP-1 to reduce inflammatory chemokine transcription. These findings suggest a diet–microbiome–metabolite strategy to prevent Salmonella colonization by breaking the pathogen–inflammation feedback loop.

Liu W, Cai J, Huang Y et al. · Cell reports · (2026) · View on PubMed ↗

Gut Microbiota and Ischemic Stroke: From Pre-Stroke Dysbiosis and Acute-Phase Changes to Therapeutic Applications.

This review summarized evidence on how the gut microbiota influences ischemic stroke through the microbiota–gut–brain axis, covering pre-stroke dysbiosis, acute-phase changes, and recovery. It synthesizes mechanisms of bidirectional communication, host modifiers, post-stroke complications, and candidate microbiota-targeted therapies. The review frames gut dysbiosis as a modifiable upstream risk factor and supports therapeutic development aimed at microbiome modulation to improve stroke outcomes.

Weng R, Dong G, Tang J et al. · Brain and behavior · (2026) · View on PubMed ↗

Biomarkers in Irritable Bowel Syndrome: Bridging Gut-Brain Mechanisms to Precision Care.

This review synthesized current evidence on biomarkers in irritable bowel syndrome (IBS) to connect gut–brain mechanisms with precision diagnosis and management. It highlighted biomarker categories spanning inflammatory mediators (e.g., cytokines, C-reactive protein), microbiota-related measures, and epithelial barrier/immune signaling indicators. The significance is that objective biomarker panels could move IBS care beyond symptom-only diagnosis toward mechanism-informed, individualized treatment.

Goyal MK, Goyal O, Chowdhary R et al. · Current gastroenterology reports · (2026) · View on PubMed ↗

Synthetic microbial communities: emerging live biotherapeutics for targeted gut microbiome modulation.

This review evaluated synthetic microbial communities (SynComs) as defined live biotherapeutics for targeted modulation of the gut microbiome, contrasting them with traditional fecal microbiota transplantation (FMT). It found that SynComs can be rationally designed using “top-down” or “bottom-up” strategies and may restore intestinal homeostasis through mechanisms such as direct targeted antagonism and immune/metabolic modulation. The scientific significance is that SynComs offer a potentially safer, compositionally controlled alternative to FMT for microbiome-based therapies.

Zhang R, Li H, Wang C et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma metabolomic signatures of migraine in 479,760 adults.

This prospective and cross-sectional analysis used nuclear magnetic resonance plasma metabolomics in 479,760 UK Biobank adults to study metabolic signatures associated with incident hospital-diagnosed migraine (6,724 cases). The key finding was a replicated HDL-related pattern with inverse associations for HDL measures and positive associations for triglyceride-rich and VLDL-related measures. These large-scale metabolomic results provide mechanistic clues linking lipid/lipoprotein biology to migraine risk and support biomarker discovery for prevention.

Hong Y, Chen F, Wang Y et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Cardiovascular disease (risk, imaging, heart failure, and hemodynamics)

Spontaneous coronary artery dissection versus atherosclerotic myocardial infarction in young women: a propensity-matched cohort study.

The study used the TriNetX research network to compare long-term outcomes in women aged 18–55 years with spontaneous coronary artery dissection (SCAD) versus atherosclerotic acute myocardial infarction (AMI) using propensity score matching. After 1:1 matching, it assessed clinical outcomes at 30 days, 1 year, and 3 years (with sensitivity analyses including age-only and BMI-only matching and SCAD without acute MI). This real-world comparative evidence helps clarify prognosis differences between SCAD and atherosclerotic AMI in young women and can guide risk counseling and management.

Awad A, Alwifati N, Echeverri D et al. · Future cardiology · (2026) · View on PubMed ↗

Coronary calcium scoring in the evaluation of stable chest pain in general practice: a cluster-randomised trial.

This cluster-randomised pragmatic trial studied whether general practitioner (GP) access to coronary artery calcium score (CACS) improves diagnostic efficiency and cardiovascular risk management in Dutch primary care patients with stable chest pain (CONCRETE). GPs were randomized by office to CACS access versus standard of care (SOC), enrolling patients aged ≥40 years (men) or ≥45 years (women) without known coronary artery disease. The significance is that if CACS improves triage of (non-)obstructive coronary artery disease, it could optimize downstream testing and risk management in primary care.

Koopman MY, Severijn TEJ, Reijnders JJW et al. · Heart (British Cardiac Society) · (2026) · View on PubMed ↗

Global, Regional, and National Burden of Stroke Attributable to High Systolic Blood Pressure in Adults Aged 45 Years and Above From 1990 to 2021, with Projections to 2045: A Systematic and Comprehensive Analysis of the Global Burden of Disease Study 2021.

This Global Burden of Disease Study 2021 analysis quantified global, regional, and national stroke mortality and disability burden attributable to high systolic blood pressure (HSBP) in adults aged ≥45 years from 1990–2021, with projections to 2045. The key finding was characterization of temporal trends (via estimated annual percentage change) and age/sex/SDI-specific patterns in HSBP-attributable stroke outcomes. These results are significant for public health planning by identifying where and how HSBP control could most effectively reduce future stroke burden.

Yu Q, Tian Y, Shen S et al. · Archives of Iranian medicine · (2026) · View on PubMed ↗

Clinical characteristics, treatment patterns, and costs among hospitalised patients with cardiomyopathy: a multicentre retrospective tertiary-hospital study across China.

This multicentre retrospective tertiary-hospital study in China analyzed clinical characteristics, treatment patterns, and direct medical costs among 15,764 adult hospitalized patients with cardiomyopathy using electronic medical records from 2017–2022. The key finding was that medical therapy alone was the most common treatment pattern (81.5%), and the study modeled factors associated with medical costs using generalized linear regression with cluster-robust standard errors. These data are significant for health-system planning by quantifying real-world utilization and cost drivers in cardiomyopathy care.

Wang L, Wang C, Zheng Y et al. · The Lancet regional health. Western Pacific · (2026) · View on PubMed ↗

Diuretic therapy for critically ill patients: a systematic review and network meta-analysis.

This systematic review and Bayesian random-effects network meta-analysis studied randomized controlled trials in critically ill adults comparing two or more diuretic strategies for active fluid removal. The key finding was an evidence synthesis of relative effectiveness across diuretic approaches, aiming to identify the optimal fluid-removal strategy in patients with preserved renal function. Scientifically and clinically, it informs guideline-level decisions on diuretic selection to improve outcomes in critically ill patients with fluid overload.

Kuriyama A, Polok K, Malhotra N et al. · Annals of intensive care · (2026) · View on PubMed ↗

EFFICACY OF PERINDOPRIL IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION.

Perindopril was evaluated in patients with heart failure with reduced ejection fraction (HFrEF) to assess efficacy, reverse cardiac remodeling, and clinical outcomes, compared against another ACE-inhibitor strategy (the abstract indicates comparison with sa—likely another regimen). The key finding was that perindopril improved therapeutic outcomes and supported reverse remodeling in the studied HFrEF cohort. This is clinically relevant because it strengthens evidence for perindopril’s role in HFrEF management where robust cohort-specific data have been limited.

Nazghaidze N, Petriashvili S, Agladze R et al. · Georgian medical news · (2026) · View on PubMed ↗

ASSESSING THE EFFECTIVENESS OF LIFESTYLE CLINIC INTERVENTIONS ON CARDIOMETABOLIC RISK FACTORS: A RETROSPECTIVE STUDY.

Lifestyle clinic interventions were studied in a retrospective cohort of 281 adult participants in Saudi Arabia (King Abdulaziz Medical City, Jeddah) over six months to assess effects on cardiometabolic risk factors. The key finding was the association between participation in a comprehensive lifestyle clinic program and changes in cardiometabolic outcomes, with participants categorized into metabolic and smoking-related groups. This supports real-world effectiveness of structured lifestyle clinic care for improving cardiometabolic risk in routine clinical settings.

Althumali Z, Khouja J, Alnemari R et al. · Georgian medical news · (2026) · View on PubMed ↗

Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis.

This systematic review and meta-analysis quantified the association between chronic obstructive pulmonary disease (COPD) and incident cardiovascular disease, incident chronic kidney disease, and death using case-control studies identified from MEDLINE and Embase. The key finding was an overall estimate of increased risk of these outcomes in people with COPD (with pooled risk ratios reported for specific endpoints such as atrial fibrillation and other cardiovascular and renal outcomes). Clinically, the results strengthen evidence that COPD is a multisystem disease with measurable downstream cardiovascular and kidney risk, informing risk stratification and prevention strategies.

Joseph T, Gao C, Nadarajah R et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Diabetes, obesity, and metabolic complications (including kidney/liver outcomes)

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.

The randomized open-label trial studied whether adding the SGLT2 inhibitor luseogliflozin to the GLP-1 receptor agonist semaglutide improves liver histology in Japanese adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. Over 52 weeks, participants received semaglutide plus luseogliflozin versus semaglutide alone with paired baseline and week-52 liver biopsies assessed by blinded pathologists. If effective, this combination could provide a histology-improving pharmacologic strategy for MASH in patients with T2D.

Miyake T, Yoshida O, Furukawa S et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N-ISM) Study.

This exploratory post hoc analysis stratified Japanese patients with type 2 diabetes (without established ASCVD) by fatty liver index (FLI) to test whether glycemic responses differ between ipragliflozin (SGLT2 inhibitor) and sitagliptin (DPP-4 inhibitor) when added to metformin. Using 52-week HbA1c change as the outcome, it compared low FLI (<51) versus high FLI (≥51) groups (n=44 and n=47, respectively) from the N-ISM trial. The results could support FLI-guided selection of second-line glucose-lowering therapy in T2D with fatty liver risk.

Kitazawa M, Katagiri T, Suzuki H et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

The liver in diabetes: current state and future perspectives.

This review summarized the current state and future directions for understanding the liver’s role in diabetes, emphasizing metabolic dysfunction-associated steatotic liver disease (MASLD) and fibrosis in type 2 diabetes. The key finding was that MASLD is common yet largely underdiagnosed (up to 95% undiagnosed) due to lack of accepted steatosis assessment recommendations, and that existing non-invasive tests may overestimate progression. This highlights an urgent need for improved diagnostic pathways and management strategies for MASLD and fibrosis to reduce diabetes-related liver complications.

Yki-Järvinen H, Roden M · Diabetologia · (2026) · View on PubMed ↗

Vascular Complications: Mechanisms and Therapeutic Perspectives.

This review studied mechanisms linking diabetic hyperglycemic microenvironments to macrophage metabolic reprogramming and polarization, focusing on how these processes drive diabetic vascular complications. It synthesized evidence that persistent low-grade inflammation and altered carbohydrate, lipid, and amino-acid metabolism promote M1/M2 imbalance via key molecular regulators. The work highlights therapeutic targets and strategies to modulate macrophage metabolism/polarization to treat or prevent diabetic vascular complications.

Wen J, Xiao K, Xu X et al. · Pharmacological research · (2026) · View on PubMed ↗

Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.

This systematic review and meta-analysis evaluated treatment-emergent adverse events related to hypertension and hypotension in patients with type 2 diabetes mellitus (T2DM) or obesity receiving tirzepatide or semaglutide. The pooled analysis (random-effects risk ratios) identified the relative risk profiles for these blood-pressure TEAEs across included trials. The results are significant for clinicians because they help quantify cardiovascular safety signals for tirzepatide versus semaglutide when used for T2DM/obesity.

Chen QX, Zhou XY, Wu Q et al. · Endocrine · (2026) · View on PubMed ↗

Renal disease and urologic conditions (AKI, CKD, podocytes, RCC salvage)

Fructose directly remodels the translocase of the outer membrane to impair oxidative phosphorylation in podocytes.

This preclinical study investigated whether intact, unmetabolized fructose can directly impair oxidative phosphorylation in podocytes by remodeling the translocase of the outer mitochondrial membrane (TOM) rather than only via fructose catabolic intermediates. The key finding is that fructose directly remodels the TOM complex to impair oxidative phosphorylation in podocytes, providing a mechanism for fructose-driven mitochondrial dysfunction. This is clinically important because it suggests that dietary fructose may directly trigger renal mitochondrial injury, informing strategies to prevent or mitigate chronic kidney disease.

Wu W, Wang W, Zhang J et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗

Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.

This randomized trial protocol studied oral microcrystalline β-NMN (MIB-626), an NAD precursor, in adults with diabetic kidney disease (DKD) to test NAD augmentation as a disease-modifying approach. The key finding is the trial design itself: a phase 2a, randomized, multicenter, double-blind, placebo-controlled study evaluating efficacy and safety of MIB-626 in DKD patients. Scientifically, it targets the mechanistic link between reduced NAD levels and DKD pathogenesis and sets up evidence generation for whether NAD augmentation can improve kidney outcomes.

Chandra MS, Gagliano-Jucá T, Shekhar S et al. · Kidney international reports · (2026) · View on PubMed ↗ · Free PDF ↗

Hallmarks of acute kidney injury: molecular endotypes, precision phenotyping, and phase-adapted therapy.

Acute kidney injury (AKI) was studied to define molecular endotypes and precision phenotypes, proposing “phase-adapted therapy” based on four interconnected pathophysiologic dimensions (initiation/effector injury, cell fate/immune microenvironment, repair/outcome, and systemic integration). The key contribution is a framework translating AKI hallmarks into measurable phenotypes using biomarkers, imaging, and functional tests to better capture temporal evolution beyond creatinine/urine output. This scientific approach aims to enable more targeted, timing-specific interventions for heterogeneous AKI patients.

Hu H, Liu Z, Ji R et al. · EBioMedicine · (2026) · View on PubMed ↗

Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.

This review examined injectable lipid-lowering therapies in advanced chronic kidney disease (CKD), emphasizing efficacy, safety, and the “dialysis paradox” in dialysis-dependent patients. It found that while statins are beneficial earlier in CKD, lipid-lowering benefit becomes less certain in advanced/end-stage disease, with outcomes complicated by reverse epidemiology and dialysis-related factors. Scientifically and clinically, the synthesis guides selection and risk–benefit assessment of lipid-lowering strategies in advanced CKD and dialysis populations.

Damianaki A, Stambolliu E, Iliakis P et al. · Cardiovascular drugs and therapy · (2026) · View on PubMed ↗

Respiratory disease (COPD, pulmonary hypertension, ciliary dyskinesia, pneumonia)

Physiotherapy in Primary Ciliary Dyskinesia-What Is the Evidence?: A Narrative Review and Personal Experience.

This narrative review assessed the evidence base for physiotherapy—especially airway clearance therapy (ACT)—in patients with primary ciliary dyskinesia (PCD), a hereditary disorder causing impaired mucociliary clearance and progressive bronchiectasis. The key finding was that, despite ACT being widely used as a cornerstone of care, evidence supporting specific physiotherapy regimens remains limited and practice varies substantially without standardized guidelines. Scientifically and clinically, the review underscores the need for higher-quality trials to define optimal ACT protocols and improve outcomes such as infection control and quality of life.

Huenaerts E, Vreys M, Vermeulen F et al. · Pediatric pulmonology · (2026) · View on PubMed ↗

Multi-omics decodes a defect-interface dual-engineered PtPb@SbO3-x nanozyme for NIR-II photothermal-amplified eradication of drug-resistant pneumonia.

This preclinical study developed a defect/interface dual-engineered PtPb@SbO3-x nanozyme for NIR-II photothermal-amplified eradication of drug-resistant pneumonia caused by multidrug-resistant bacteria. The key finding was that the engineered nanozyme enabled precisely regulated reactive oxygen species generation and improved photothermal/chemodynamic synergy under NIR-II irradiation to enhance bacterial killing. Clinically, it proposes a non-antibiotic therapeutic platform to overcome limitations of conventional photothermal therapy and reduce treatment challenges in MDR pneumonia.

Qiu Z, Wang D, Jin Z et al. · Materials today. Bio · (2026) · View on PubMed ↗

Polygonum cuspidatum Exosome-Like Nanovesicles Alleviate Hypoxic Pulmonary Hypertension by Stabilizing PON1 to Inhibit MAPK-Mediated PASMC Phenotypic Switching.

This study investigated whether Polygonum cuspidatum exosome-like nanovesicles (PCELNs) treat hypoxic pulmonary hypertension (HPH) in a mouse model by stabilizing PON1 to block MAPK-driven phenotypic switching of pulmonary artery smooth muscle cells (PASMCs). PCELNs were characterized by transmission electron microscopy, dynamic light scattering, and immunofluorescence, and the treatment improved hemodynamics and pulmonary vascular pathology while modulating the PON1–MAPK axis. The work supports PCELNs as a potential mechanism-based therapeutic strategy for HPH targeting PON1-mediated inhibition of PASMC phenotypic switching.

Chen B, Hu J, Pan X et al. · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · (2026) · View on PubMed ↗

Infectious disease (bacterial/viral infections, antivirals, and epidemiology)

HLA-DQ allotypes in adults screened for celiac disease reveal historical misdiagnosis - results from the HUNT study.

This population-based HUNT4 study examined HLA-DQ allotypes in Norwegian adults screened for celiac disease to assess whether historical misdiagnosis occurred. Using HLA-DQA1 and HLA-DQB1 sequencing in anti-TG2–seropositive subjects and controls, the study found that all newly detected cases were DQ2 or DQ8 positive, while a subset of known cases were DQ2 and DQ8 negative. The significance is that HLA-DQ genotyping can help identify likely misdiagnosed celiac disease in adults and improve diagnostic accuracy in screening programs.

Hjort R, Andersen IL, Lukina P et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · (2026) · View on PubMed ↗

A Decade of Screening and Treating Helicobacter pylori Infection Among First-Year High School Students in Kyoto, Japan: Annual Trends in Infection, Consultation, and Eradication Success Rates (2015-2023).

This prospective cohort study followed first-year high school students in Kyoto Prefecture, Japan (2015–2023) using a urine H. pylori antibody primary screen and stool antigen confirmation in a school-based “screen-and-treat” program. Over the decade, the study tracked annual trends in infection rates, consultation uptake, and eradication success after confirmed positivity. These longitudinal real-world data support adolescent screening as a strategy to prevent progression to advanced gastric atrophy and thereby reduce future gastric cancer risk.

Handa O, Uchiyama K, Takagi T et al. · Helicobacter · (2026) · View on PubMed ↗

TOLLIP suppresses picornavirus internalization by targeting and degrading VP1 protein through selective autophagy.

This study investigated the host restriction mechanism against foot-and-mouth disease virus (FMDV) by analyzing how TOLLIP suppresses viral internalization through selective autophagy targeting of the viral capsid protein VP1. It found that the chaperone DNAJA3 recruits the autophagy cargo receptor TOLLIP to facilitate selective autophagic degradation of VP1, with TOLLIP directly interacting with VP1 residues 1–37. These results identify a specific DNAJA3–TOLLIP autophagy axis that can restrict FMDV by promoting VP1 clearance, informing antiviral strategies that harness selective autophagy.

Zhang W, Yang Y, Shao W et al. · Autophagy · (2026) · View on PubMed ↗

Protein-Protein Interactions Between Peptidoglycan, Lipopolysaccharide, and Phospholipid Biosynthesis Enzymes in Escherichia coli.

The study investigated protein–protein interactions among Escherichia coli envelope biosynthesis enzymes by focusing on how peptidoglycan (PG), lipopolysaccharide (LPS), and phospholipid (PL) pathways are coordinated through the LapB (YciM) scaffold. Using bacterial two-hybrid assays (and related interaction approaches), it tested whether MurA, the first committed PG biosynthesis enzyme, is an integral component of the LapB complex. The findings clarify how shared precursor usage (UDP-GlcNAc) and envelope biogenesis are coordinated at the protein-interaction level, informing models of bacterial envelope homeostasis.

Tilg LJ, Weber S, Bille H et al. · Chembiochem : a European journal of chemical biology · (2026) · View on PubMed ↗

Pediatric brucellosis: predictors of hospitalization, complications, and relapse in a nationwide multicenter cohort.

This nationwide multicenter retrospective cohort study in Türkiye analyzed pediatric brucellosis cases (ages 0–18 years; n=1052) to identify predictors of hospitalization, complications, and relapse. Using multiple backward logistic regression with Firth penalization, it determined independent risk factors associated with these adverse outcomes. The findings are clinically important for risk stratification and targeted follow-up in children with brucellosis in endemic settings.

Kuruc AI, Aykac K, Cakici O et al. · European journal of pediatrics · (2026) · View on PubMed ↗

Disease characteristics of SEPSECS deficiency: an international, retrospective, multicenter cohort study.

This international retrospective multicenter cohort study characterized disease features in 27 individuals with biallelic SEPSECS variants, using broad biochemical correlation, focused metabolomics, and structural plus in vitro activity analyses. The authors identified 13 previously unreported SEPSECS variants and proposed three clinical courses—severe early-onset with cerebellar/cerebral atrophy, milder early-onset with gradual deterioration, and late-onset mild disease—highlighting predominant brain involvement. These genotype–phenotype and biochemical findings improve diagnosis and clinical counseling for SEPSECS-related selenoprotein biosynthesis disorders.

Killam BY, Knol MJ, Fradejas-Villar N et al. · Genetics in medicine : official journal of the American College of Medical Genetics · (2026) · View on PubMed ↗

Hematology and coagulation disorders (ITP, CAR-T, AML/MDS, immune cell regulation)

Reduced SRSF1 Expression Correlates with LCK Exon Skipping and Impaired Treg Induction in Immune Thrombocytopenia.

The study investigated immune thrombocytopenia (ITP) by comparing CD4+ naive T cells from ITP patients versus healthy controls and analyzing alternative splicing changes affecting T-cell receptor (TCR) signaling and regulatory T-cell (Treg) induction. It showed reduced SRSF1 expression in ITP associates with LCK exon 8 skipping, and using an LCK minigene plus RNA pull-down mass spectrometry and RNA immunoprecipitation identified SRSF1 as a key splicing factor driving proper LCK exon inclusion. This links a specific splicing regulator (SRSF1) to impaired LCK-mediated Treg differentiation in ITP, suggesting a potential molecular target to restore immune regulation.

Hu X, Leng S, Liu Y et al. · Blood · (2026) · View on PubMed ↗

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

This analysis of the ADVANCE IV trial evaluated the effect of efgartigimod IV on immature platelet fraction (IPF) in patients with primary immune thrombocytopenia (ITP). The key finding is that FcRn blockade with efgartigimod decreases IPF, consistent with reduced IgG autoantibody–mediated platelet degradation. This is clinically significant because IPF may serve as a pharmacodynamic biomarker and efgartigimod could improve hematologic outcomes in primary ITP.

Al-Samkari HT, Matthijssens F, Nishiwaki K et al. · British journal of haematology · (2026) · View on PubMed ↗

CAR-FIT: CAR-T fitness index for therapy - integrating comorbidity and geriatric assessments to guide safe and equitable delivery of CAR-T in patients with borderline physiological reserve.

CAR-FIT was studied in 80 adults with relapsed diffuse large B-cell lymphoma receiving CAR-T therapy (2020–2025) to create an objective CAR-T fitness index integrating frailty and comorbidity/geriatric assessments. The study found that CAR-FIT stratified patients with borderline physiological reserve and was associated with overall survival, progression-free survival, and severe treatment-related complications such as grade ≥3 cytokine release syndrome (CRS). This supports using a standardized fitness index to improve safe, equitable CAR-T patient selection and resource allocation.

Wong KL, Ng LCK, Lim NA et al. · Transplantation and cellular therapy · (2026) · View on PubMed ↗

Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies.

Azacitidine was evaluated in a prospective open-label phase II trial in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) with reduced-intensity conditioning from matched related or unrelated donors. Pre-transplant epigenetic priming with azacitidine was designed to enhance chemosensitivity and improve alloHCT outcomes compared with historical expectations, with the trial assessing transplant-related endpoints. If effective, this approach would provide a practical epigenetic strategy to reduce relapse after alloHCT in high-risk myeloid malignancies.

Alhomoud M, Tokumori FC, Chokr N et al. · Transplantation and cellular therapy · (2026) · View on PubMed ↗

Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results.

This observational Berolife study evaluated tolerability and effectiveness of the once-daily oral prophylactic drug berotralstat in 80 French patients with hereditary angioedema (HAE). After initiation, the study assessed HAE attack rate using paired Wilcoxon testing and reported real-world tolerability and effectiveness outcomes (with enrollment of 80 patients). These findings support the clinical use of berotralstat as first-line prophylaxis by characterizing its safety and attack-rate impact in routine practice.

Gobert D, Launay D, Boccon-Gibod I et al. · Clinical and translational allergy · (2026) · View on PubMed ↗

Calibration of CAR signaling promotes asymmetric cell division to direct CAR-T cell fate and antitumor potency.

This study examined how engineered chimeric antigen receptor (CAR) signaling controls asymmetric cell division (ACD) and fate decisions in CAR-T cells. Antigen engagement induced ACD through polarized inheritance of the CAR immune synapse (CARIS), producing CARhigh progeny with a short-lived effector-like state and CARlow progeny with memory-like features that showed enhanced persistence and superior antitumor efficacy. Calibrating CAR signaling strength therefore emerges as a tunable design principle to improve CAR-T potency by directing cell fate.

Shen X, Xu X, Jiang J et al. · Cell reports · (2026) · View on PubMed ↗

Clinical prediction, biomarkers, and trial methodology (risk stratification, prognostic tools, ML, adverse events)

Comparison of a Computable Pediatric Sepsis Phenotype Tool in Argentinian and U.S. Cohorts.

The study evaluated whether computable pediatric sepsis phenotypes (PedSep A–D) previously derived in a U.S. cohort are plausible in an independent Argentine cohort using the ESSPED2 registry. It compared phenotype distributions and feasibility across 51 pediatric intensive care units in Argentina (and matched to the U.S. PICU dataset) to support use in personalized clinical trials across Pan-American children. If validated, this cross-cohort computable phenotyping tool could standardize sepsis stratification for targeted pediatric interventions.

Caldino Bohn RI, Galvan ME, Lanziotti VS et al. · Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · (2026) · View on PubMed ↗

Defining ‘psychedelic’.

This article examined the concept and definition of “psychedelic” by analyzing the phenomenology and principal subjective effects of three psychoactive drugs—psilocybin, ketamine, and MDMA—in over 200 participants. It argues that the term should be treated as a taxonomic category grounded in phenomenology rather than only a transient state. Scientifically, this reframes how “psychedelic” is operationalized for research and may improve consistency across clinical and experimental studies.

Ostrand AE, Nour MM, Timmermann C et al. · Journal of psychopharmacology (Oxford, England) · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Early Comprehensive Geriatric Assessment in Acute Care: Evidence and Implementation.

This article reviewed evidence and implementation considerations for early comprehensive geriatric assessment (CGA) in acute care settings for older adults, particularly those at risk of frailty-related adverse outcomes. The key finding was that introducing CGA earlier—rather than after admission—may improve individualized decision-making and better align care with medical, functional, psychological, and social needs. Clinically, it supports operationalizing earlier frailty recognition to reduce delirium, functional decline, prolonged hospitalization, and mortality.

Ducker E · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.

This population-based cohort study analyzed recovery trajectories and predictors of symptom resolution in adults with post-COVID-19 condition (PCC) using the Lifelines prospective cohort with repeated symptom questionnaires from 2020–2022. The key finding was characterization of how recovery progresses over time in the general population and identification of predictors of symptom resolution while accounting for pre-infection symptom levels and differences by symptom severity. Clinically, it helps forecast PCC prognosis and supports earlier, more targeted interventions based on individual recovery trajectories.

Brunet JL, van Ockenburg SL, Leyli-Abadi M et al. · The Lancet regional health. Europe · (2026) · View on PubMed ↗

Machine learning to predict adverse perinatal outcomes: a systematic review and meta-analysis.

This systematic review and meta-analysis studied machine learning (ML) models that predict adverse perinatal outcomes (including preterm birth and small for gestational age) using routine clinical data, and compared performance and bias risk against logistic regression. The key finding was an assessment of current evidence on ML model accuracy, comparative effectiveness versus traditional regression, and overall risk of bias across studies. Clinically, it clarifies how ready ML tools are for perinatal risk prediction and where methodological improvements are needed before implementation.

Zhang J, Daniel N, Tiranti A et al. · EClinicalMedicine · (2026) · View on PubMed ↗

Transoesophageal echocardiography during cardiopulmonary resuscitation for cardiac arrest: A scoping review.

This scoping review studied the evidence on transoesophageal echocardiography (TEE) performed during cardiopulmonary resuscitation (CPR) in adults with in-hospital or out-of-hospital cardiac arrest. It mapped studies evaluating intra-arrest TEE outcomes including survival, neurological status, return of spontaneous circulation, CPR quality metrics, and diagnostic findings/management impact. The significance is that it identifies what is known—and what remains uncertain—about whether intra-arrest TEE improves patient outcomes during resuscitation.

Scquizzato T, Zelop CM, Purkarthofer D et al. · Resuscitation · (2026) · View on PubMed ↗

Drug-associated bipolar disorder: A disproportionality analysis of the FAERS database.

Drug-associated bipolar disorder risk was studied using a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database from Q1 2004 to Q3 2025. The analysis identified high–bipolar disorder risk drugs and evaluated whether drug labels contained BD-related warnings, using MedDRA v27.1 preferred terms and sex- and subtype-stratified disproportionality methods. This is clinically significant for pharmacovigilance by helping regulators and clinicians recognize medications with disproportionate BD reporting signals.

Du P, Chen X, Zhang W et al. · Psychiatry research · (2026) · View on PubMed ↗

Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients.

Ataxia severity progression was studied in 219 patients with SCA27B, an autosomal-dominant ataxia caused by GAA repeat expansions in FGF14, using longitudinal multicentre observational data (2015–2024) and item-level analyses of the Scale for the Assessment and Rating of Ataxia (SARA). The study characterized how SARA metrics change over time, how they depend on age-related impairment, and what modifiers influence progression. These results are significant for trial design by improving precision in outcome measurement and expectations for disease progression in SCA27B.

Traschütz A, Hilgers RD, Erdlenbruch F et al. · EBioMedicine · (2026) · View on PubMed ↗

Artificial intelligence in cardiovascular care: a systematic review and meta-analysis of randomised controlled trials.

This systematic review and meta-analysis synthesized randomized controlled trials evaluating AI-enabled interventions in cardiovascular care and assessed trial design, system characteristics, and methodological quality and reporting transparency. The key finding was that evidence from RCTs is heterogeneous and varies in effectiveness and reporting quality across AI applications, limiting certainty about clinical impact. Scientifically, the review maps where AI cardiovascular trials are strongest and where standards for evaluation and transparency need improvement before broad clinical adoption.

Ong AQC, Ang CS, Bojic I et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Generated automatically on August 18, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.

← All Trending Digests